SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Versant Venture Capital VI, L.P., et al. – ‘4’ for 7/21/20 re: Pandion Therapeutics, Inc.

On:  Tuesday, 7/21/20, at 7:41pm ET   ·   For:  7/21/20   ·   Accession #:  899243-20-19877   ·   File #:  1-39381

Previous ‘4’:  ‘4/A’ on 7/10/20 for 1/7/20   ·   Next:  ‘4’ on 7/29/20 for 7/27/20   ·   Latest:  ‘4’ on 4/11/24 for 4/9/24

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 7/21/20  Versant Venture Capital VI, L.P.  4                      1:20K  Pandion Therapeutics, Inc.        Donnelley Fin’l S… 06/FA
          Versant Vantage I, L.P.
          Versant Ventures VI GP, L.P.
          Versant Ventures VI GP-GP, LLC
          Versant Vantage I GP, L.P.
          Versant Vantage I GP-GP, LLC

Statement of Changes in Beneficial Ownership of Securities by an Insider   —   Form 4   —   SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 4           Form 4 Submission -- doc4.xml/3.6                   HTML      3K


        

This ‘4’ Document is an XML Data File that may be rendered in various formats:

  Form 4    –   Plain Text   –  SEC Website  –  EDGAR System  –    XML Data    –  <?xml?> File
 
 
SEC Info℠ rendering:  Form 4 Submission
 
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
  
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Versant Venture Capital VI, L.P.
(Last)(First)(Middle)
ONE SANSOME STREET, SUITE 3630
(Street)
SAN FRANCISCOCA94104
(City)(State)(Zip)
2. Issuer Name and Ticker or Trading Symbol
Pandion Therapeutics, Inc. [ PAND ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
DirectorX10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
7/21/20
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
Form filed by One Reporting Person
XForm filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock 7/21/20C 3,176,507A (1)3,176,507D (2)
Common Stock 7/21/20C 577,544A (1)577,544ISee footnote (3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Series A Preferred Stock (1) 7/21/20C 14,452,795 (1) (1)Common Stock2,834,220$0.000D (2)
Series B Preferred Stock (1) 7/21/20C 1,745,458 (1) (1)Common Stock342,287$0.000D (2)
Series B Preferred Stock (1) 7/21/20C 1,245,330 (1) (1)Common Stock244,211$0.000ISee footnote (3)
Simple Agreement for Future Equity (4) 7/21/20C 333,333 (4) (4)Common Stock333,333$0.000ISee footnote (3)
1. Name and Address of Reporting Person*
Versant Venture Capital VI, L.P.
(Last)(First)(Middle)
ONE SANSOME STREET, SUITE 3630
(Street)
SAN FRANCISCOCA94104
(City)(State)(Zip)
1. Name and Address of Reporting Person*
Versant Vantage I, L.P.
(Last)(First)(Middle)
ONE SANSOME STREET
SUITE 3630
(Street)
SAN FRANCISCOCA94104
(City)(State)(Zip)
1. Name and Address of Reporting Person*
Versant Ventures VI GP, L.P.
(Last)(First)(Middle)
ONE SANSOME STREET
SUITE 3630
(Street)
SAN FRANCISCOCA94104
(City)(State)(Zip)
1. Name and Address of Reporting Person*
Versant Ventures VI GP-GP, LLC
(Last)(First)(Middle)
ONE SANSOME STREET
SUITE 3630
(Street)
SAN FRANCISCOCA94104
(City)(State)(Zip)
1. Name and Address of Reporting Person*
Versant Vantage I GP, L.P.
(Last)(First)(Middle)
ONE SANSOME STREET
SUITE 3630
(Street)
SAN FRANCISCOCA94104
(City)(State)(Zip)
1. Name and Address of Reporting Person*
Versant Vantage I GP-GP, LLC
(Last)(First)(Middle)
ONE SANSOME STREET
SUITE 3630
(Street)
SAN FRANCISCOCA94104
(City)(State)(Zip)
Explanation of Responses:
(1)  The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
(2)  The reportable securities are owned directly by Versant Venture Capital VI, L.P. ("Versant VI"). Versant Ventures VI GP, L.P. ("Versant Ventures VI GP") is the general partner of Versant VI, and Versant Ventures VI GP-GP, LLC ("Versant Ventures VI GP-GP") is the general partner of Versant Ventures VI GP. Versant Ventures VI GP and Versant Ventures VI GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant VI, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.
(3)  The reportable securities are owned directly by Versant Vantage I, L.P. ("Versant Vantage I"). Versant Vantage I GP, L.P. ("Versant Vantage I GP") is the general partner of Versant Vantage I, and Versant Vantage I GP-GP, LLC ("Versant Vantage I GP-GP") is the general partner of Versant Vantage I GP. Versant Vantage I GP and Versant Vantage I GP-GP may be deemed to indirectly beneficially own the shares beneficially owned by Versant Vantage I, but disclaim beneficial ownership except to the extent of their pecuniary interest therein.
(4)  The Simple Agreement for Future Equity converted into Common Stock automatically upon the closing of the Issuer's initial public offering and had no expiration date.
Remarks:
/s/ Versant Venture Capital VI, L.P. By: Versant Ventures VI GP, L.P. Its: General Partner By: Versant Ventures VI GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 7/21/20
/s/ Versant Vantage I, L.P. By: Versant Vantage I GP, L.P. Its: General Partner By: Versant Vantage I GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 7/21/20
/s/ Versant Ventures VI GP, L.P. By: Versant Ventures VI GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 7/21/20
/s/ Versant Vantage I GP, L.P. By: Versant Vantage I GP-GP, LLC Its: General Partner By: Robin L. Praeger Its: Managing Director 7/21/20
/s/ Versant Ventures VI GP-GP, LLC By: Robin L. Praeger Its: Managing Director 7/21/20
/s/ Versant Vantage I GP-GP, LLC By: Robin L. Praeger Its: Managing Director 7/21/20
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
____________
Transaction Code:
    C    Conversion of derivative security.

↑Top
Filing Submission 0000899243-20-019877   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Sun., Apr. 28, 3:57:48.2pm ET